Inada 2023 — Heavy metal regulations in herbal medicines across nine pharmacopoeias
This paper compares the heavy metal regulatory limits for herbal medicines (Pb, Cd, Hg, As) as specified in nine major pharmacopoeias: Japanese (JP), European (EP), United States Pharmacopeia (USP), Chinese (ChP), Korean (KP), Taiwanese (TaiwanP), Indian (IP), British (BP), and the WHO guidelines. The analysis reveals substantial variation in allowable limits across jurisdictions, with some pharmacopoeias applying much stricter thresholds than others for the same analytes and matrices.
Key numbers
The paper tabulates specific limit values for Pb, Cd, Hg, and As across all nine pharmacopoeia frameworks. Key findings include inter-jurisdictional variation of several-fold for the same metal across regulatory systems. The WHO guidelines generally set a baseline, with individual pharmacopoeias either adopting them directly or imposing tighter national standards. Specific numeric limits are provided by analyte and pharmacopoeia in the source tables.
Methods (brief)
Literature and regulatory document review; no experimental analytical measurement. Comparison is presented as a structured table of official published limits for each metal-pharmacopoeia combination.
Implications
Certification: Directly relevant to HMT&C international market positioning — brands selling herbal products into multiple jurisdictions face varying compliance thresholds. The strictest applicable limit governs.
Courses: Core reference for module on regulatory frameworks and global harmonisation of botanical supplement standards.
App: Useful for flagging jurisdiction-specific regulatory risk on herbal/botanical ingredient pages.
Microbiome: Not applicable.